ACXP Latest Press Releases

-- October 26, 2026 --

Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update PRNewswire 8:02 AM

-- October 21, 2026 --

Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect PRNewswire 8:02 AM

-- September 29, 2026 --

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection PRNewswire 8:01 AM

-- August 17, 2026 --

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat PRNewswire 8:01 AM

-- August 14, 2026 --

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update PRNewswire 7:01 AM

-- August 12, 2026 --

Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics PRNewswire 8:01 AM

-- August 10, 2026 --

Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics PRNewswire 8:01 AM

-- August 3, 2026 --

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection PRNewswire 8:00 AM

-- July 14, 2026 --

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection PRNewswire 8:00 AM

-- July 8, 2026 --

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update PRNewswire 8:00 AM

-- June 16, 2026 --

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference PRNewswire 8:00 AM

Market Data Delayed 15 Minutes